A variety of methods are available to determine HIV-1 co-receptor usage, commonly referred to as viral tropism. This article reviews recent data on phenotypic and genotypic assays of HIV-1 tropism.
Introduction
Discovery of the two main co-receptors for HIV-1, CCR5 and CXCR4, has lead to a better understanding of the interaction of the viral envelope with host cells and the development of novel therapeutic agents that inhibit viral entry. Viral tropism assays play an important role in identifying patients who are candidates for treatment with entry inhibitors and in the ongoing development of co-receptor antagonists as a novel class of antiretroviral agents. In addition, epidemiological data on co-receptor usage are important for elucidating the relationship between co-receptor usage and disease progression. Here we provide an overview of the major methods and tools used to determine HIV co-receptor usage and discuss the utility of tropism testing in the clinical setting.
Viral entry and tropism
HIV-1 entry into susceptible cells is initiated by attachment of the surface subunit of the envelope glycoprotein (gp120) to CD4 molecules on the cell surface. Subsequently, binding of gp120 to a specific C-C or C-X-C chemokine receptor triggers conformational changes in the transmembrane subunit of envelope (gp41) that lead to membrane fusion and entry of the viral core particle into the cell. Although a number of chemokine receptors can be utilized by HIV-1 for entry in vitro, the two most significant co-receptors in vivo are CCR5 and CXCR4 (reviewed in [1] ). Soon after infection, most patients harbor HIV-1 that easily infects macrophages and primary lymphocytes, but not immortalized T-cell lines (M-tropic virus). Later in infection, more cytopathic variants can be isolated that have acquired the ability to replicate in immortalized T cell lines, such as H9 or MT-2 cells, but have lost the ability to infect macrophages (T-tropic viruses) [2] . Because viral replication in these T-cell lines causes cytopathic changes and syncytium formation, such isolates were termed syncytium-inducing viruses. In comparison, M-tropic viruses do not replicate on T-cell lines, and hence are termed nonsyncytium-inducing viruses. When the role of CCR5 and CXCR4 in HIV-1 entry was discovered, it became apparent that viruses with syncytium-inducing phenotype preferentially use CXCR4 co-receptors, which are expressed on MT-2 cells, whereas nonsyncytium-inducing strains use CCR5 co-receptors, which are absent from this particular cell line. Viruses that preferentially use CCR5 as co-receptor are termed R5 viruses; those that use CXCR4 are termed X4 viruses. Because it is difficult to distinguish mixtures of R5 and X4 viruses from dual-tropic strains with currently available assays, viruses that are capable of using both CCR5 and CXCR4 co-receptors are often referred to as dual/mixedtropic (D/M) viruses.
Tools for determining viral tropism
Currently, there are several methods to determine HIV-1 tropism, but it is unclear which will prove most appropriate for routine clinical use. Although clinical trials of chemokine receptor antagonists have relied on phenotypic assays, such assays are laborious, time-consuming and expensive. More rapid and less costly options include genotypic methods that predict co-receptor usage based on the env gene sequence. Each of these approaches has advantages and limitations, and both share the common challenge of detecting low levels of CXCR4-using viruses present as minority variants in the viral quasi-species. Understanding the limitations of each of these assays is important for making the best clinical use of their results.
Phenotypic methods
Phenotypic testing to determine viral tropism has depended on two general approaches: detection of syncytium formation by HIV-1 on MT-2 cells or detection of viral infection of nonlymphoid cell lines that stably express CD4 and CCR5 or CXCR4.
MT-2 cell assay
Early assays to characterize the tropism of HIV-1 isolates depended on the differential ability of T-tropic and Mtropic viruses to infect cells of an human T-cell leukemia virus type I (HTLV-1) transformed lymphoblastoid cell line (MT-2 cells) [2,3]. The MT-2 assay requires first stimulating peripheral blood mononuclear cells (PBMCs) from HIV-1-infected patients to increase viral replication. Subsequently, supernatant from the culture is used to infect MT-2 cells; alternatively, the stimulated PBMCs can be co-cultured directly with MT-2 cells. Cultures are examined at regular intervals for cytopathic changes and syncytium formation, which generally are observed within 14 days when CXCR4-using variants are present. Cells or culture supernatant are inoculated onto phytohemagglutinin (PHA)-stimulated PBMCs from seronegative donors and monitored for p24 antigen production as a control to insure the presence of infectious virus in the sample. The use of stimulated patient PBMCs as a source of infectious virus has advantages and disadvantages. The resulting virus stock may represent both circulating and archived populations of HIV; conversely, PBMC-derived virus may not accu-rately reflect the full diversity of the plasma virus population, and may have been altered by selection even during brief in-vitro passage.
The presence of syncytium-inducing virus is correlated with accelerated CD4 cell count decline, increased plasma HIV-1 RNA levels, disease progression and more frequent opportunistic infections [4, 5] . Although syncytium-inducing viruses are found in all stages of HIV-1 infection, they are most commonly detected in patients with advanced disease. Before the advent of potent antiretroviral therapy, syncytium-inducing virus could be detected in approximately 25% of infected persons within 5 years of seroconversion [6] . Although it became clear that the formation of syncytia in MT-2 cells indicates CXCR4 usage, the correlation between syncytium-inducing phenotype and co-receptor usage has proved to be more complex as new ways of testing for viral tropism have been introduced and larger cohorts of patients are studied. For instance, the syncytium-inducing phenotype can be observed with either pure X4 or D/M viruses, but studies suggest distinct clinical correlations associated with pure X4 and D/M viruses [7] [8] [9] .
Assays of co-receptor usage
Once it became clear that HIV-1 tropism was related to co-receptor usage, several reporter cell lines were developed that express various combinations of HIV-1 receptors on the cell surface. These cell lines are able to support replication of primary HIV-1 isolates, infectious molecular clones or pseudo-typed viruses. Virus replication can be detected by p24 antigen production or by expression of a reporter gene. Most phenotypic assays now use human glioma cell lines (e.g., U87, U373 or NP-2 cells) that stably express CD4 and either CCR5 or CXCR4. Advantages of these cell lines include their ability to easily support HIV replication, the high level of co-receptor expression and the adherent property of the cells, which makes them easier to work with in cell culture. An important caveat is that the high levels of coreceptor expression exceed those found on primary lymphocytes and monocytes in vivo. Some studies suggest that co-receptor usage may be affected by the level of co-receptor expression, whereas others do not [10, 11] . Another frequently used indicator cell line is the GHOST cell line, which is derived from human osteosarcoma cells and carries a GFP gene under the control of HIV-1 Tat, in addition to expressing CD4 and CCR5 or CXCR4 [12] . A disadvantage of these cells is that they naturally express low levels of CXCR4, which can produce misleading results [13] .
Phenotypic assays with recombinant or pseudo-typed viruses
Phenotypic assays developed by clinical reference laboratories utilize recombinant or pseudo-typed viruses constructed with envelope sequences amplified from patient plasma by RT-PCR. The resulting env amplicons preserve the diversity of the plasma virus population and avoid any selection imposed by in-vitro passage. Reliable representation of viral diversity depends largely on the sensitivity and accuracy of the RT-PCR reactions, which is partly a function of the plasma virus load. Typically, the virus load should be above 1000 copies/ml in order to obtain a reliable result.
The most widely used phenotypic test in clinical trials of CCR5 antagonists is the Trofile assay [Monogram Biosciences Inc., South San Francisco, California; now Laboratory Corporation of America (LabCorp)]. The env gene is amplified from plasma HIV-1 RNA and cloned into an expression vector, which is then co-transfected together with an env-deficient HIV genomic vector carrying a luciferase reporter gene into human embryonic kidney cells (HEK293). The resulting pseudo-typed HIV particles are harvested and inoculated onto U87:CXCR4 and U87:CCR5 cells. Samples that produce a signal [measured as relative light units (RLUs) in a luciferase assay] only on CCR5-expressing cells are considered R5, and those that produce a signal only on CXCR4-expressing cells are considered X4; those that produce a signal on both cell types are considered dual or mixed tropic (D/M). Signal ablation with specific co-receptor inhibitors is used for each co-receptor to confirm the assigned tropism. Viruses with an syncytium-inducing phenotype by MT-2 assay produce high RLUs when inoculated onto CXCR4-expressing U87 cells. The original Trofile assay reliably detected X4 variants present at 10% of the viral population, but only detected variants present at 5% of the population in 85% of assays [14] .
Several other laboratories have developed phenotypic assays to determine HIV-1 tropism, all based on the same principles as the Trofile assay. As of this writing, however, none of these alternative assays is commercially available.
Detection of minority species by phenotypic assays
An important limitation of the original Trofile assay was the challenge of detecting low abundance (minority) CXCR4-using variants. Clinical trials of CCR5 antagonists that employed the original Trofile assay to identify patients with exclusively R5 virus have found that 5-10% of patients judged to have R5 virus at screening had D/M virus at entry [9, 15 ] . The apparent change in co-receptor usage most likely is explained by small shifts in minority CXCR4-using variants above and below the limit of assay sensitivity [16 ] . Patients with initially undetected D/M viruses who subsequently received a CCR5 antagonist showed a blunted virologic response and high rates of early virologic failure [15 ,17,18 ] . However, assays using replicating viruses did not sub-stantially increase the ability to detect presence of CXCR4-using virus [16 ] . Enhancements to the Trofile assay have improved its sensitivity for detecting minority CXCR4-using variants. The current assay is validated to detect X4 variants present at 0.3% of the population with 100% sensitivity [19, 20] . However, actual sensitivity in clinical samples may vary as a function of virus load and infectivity of the virus being assayed.
The enhanced Trofile assay has been applied retrospectively to retest screening samples from patients who enrolled in two clinical trials of CCR5 antagonists, and the data reanalyzed based on the resulting reclassification of eligible patients. The MERIT study compared the efficacy of maraviroc with that of efavirenz (both given with a fixed-dose combination of zidovudine plus lamivudine) as initial antiretroviral therapy. The primary analysis of that trial showed that the maraviroc arm failed to achieve the prespecified threshold for noninferiority to efavirenz. Screening and study entry were two separate time points. Patients had to have R5 virus at screening to be eligible for the study. However, a fraction of those patients actually had D/M virus that went undetected at screening but was D/M at entry [21] ; most such patients experienced virologic failure on maraviroc [22] . They would have been identified by a more sensitive tropoism assay. Similarly, the enhanced Trofile assay reclassified 25 of 114 (22%) patients enrolled into AIDS Clinical Trials Group (ACTG) protocol A5211, a phase 2b trial of vicriviroc in treatment-experienced patients, as D/M from the assignment of R5 virus by the original Trofile assay [23] . Nevertheless, the enhanced Trofile assay identified D/M virus in the screening samples from only 12 of 23 (52%) vicriviroc recipients in whom CXCR4using virus subsequently emerged, suggesting room for further improvements in assay sensitivity [23] .
Genotypic methods for determining HIV-1 tropism Genetic approaches to viral tropism are based on the principle that the V3 loop is the major determinant of coreceptor usage. Bioinformatic algorithms to determine co-receptor usage are based on known genotype and phenotype pairs and have been shown to perform relatively well in clonal samples [24] . Genotyping has several advantages over phenotyping, including lower cost and shorter turn-around time. Sequencing avoids certain confounders inherent to phenotypic assays, such as lack of standardization among laboratories that were performing the assays, differences in activity of different target cells, subjective interpretation of cytopathic changes and the need to use stimulated or pseudo-typed viruses. In addition, some authors argue that genotyping may be able to differentiate levels of CXCR4 utilization by scoring V3 sequences on a continuous scale. Fluctuations in this continuous index may detect and predict shifts in phenotype even before the emergence of biological markers [25] . However, genotypic methods fail to achieve high sensitivity and this might be explained in two ways. First, several studies show that regions outside of the V3 loop are important determinants of co-receptor usage [26, 27] . Second, the detection of minority species in bulk sequencing is limited even when sequences are expanded into numerous possible permutations.
The 11/25 rule
The simplest genotypic approaches for predicting coreceptor usage include the presence of positively charged amino acids at positions 11 and 25, often referred as the '11/25 rule', and total charge of V3 loop equal to or greater than þ5 [28, 29] . The 11/25 rule is fairly sensitive for distinguishing nonsyncytium-inducing and syncytiuminducing viruses, suggesting that the amino acid changes at these positions contribute to the viral phenotype on MT-2 cells. With clonal HIV sequences, the 11/25 rule has more than 90% sensitivity and specificity for predicting the syncytium-inducing phenotype [24] . However, this rule has less than 60% sensitivity in terms of predicting CXCR4 usage, underscoring the point that the syncytium-inducing phenotype and co-receptor usage are not synonymous [30] . The sensitivity and specificity of the 11/25 rule are further reduced when applied to population-based V3 loop sequences. Using direct PCR and population-based sequencing, the 11/25 rule has a reported specificity of 93.1% but sensitivity of 32.7% for predicting X4 virus when compared with the phenotype assigned by the Trofile assay [31] . The sensitivity of genotypic predictions of co-receptor usage may be improved by integrating CD4 cell count and other clinical factors into the evaluation [32 ] .
Despite their overall low sensitivity, these rules-based approaches are good predictors of the risk of clinical progression in the absence of antiretroviral therapy (ART) [28, 29] . Similarly, two studies of treatmentexperienced cohorts showed that presence of CXCR4using virus, as determined by the 11/25 rule, was associated with a significantly lower CD4 cell count and poorer immunological response to ART [33, 34] . In a prospective cohort study of patients initiating ART, those whose virus was X4 by the 11/25 genotype had earlier mortality after starting therapy despite achieving viral suppression to less than 500 copies/ml [relative risk (RR) 1.70, P ¼ 0.027] compared with patients without the 11/25 genotype. This multivariate analyses controlled for viral load, CD4 cell count and time spent on ART in the first year of follow-up [33] .
Bioinformatics approaches
A number of bioinformatic approaches for interpreting V3 amino acid sequences has been developed to predict HIV co-receptor usage, including decision trees, support vector machines (SVMs), neural networks (NNs) and position-specific scoring matrices (PSSMs). The SVMs generate a categorical score of R5 or X4; the SVMgenomiac uses an amino acid dataset aligned to a standard, whereas SVM-geno2pheno uses an unaligned nucleotide dataset as input [35] . Neural network algorithms use a large population-based sequence dataset from samples with known syncytium-inducing phenotype and/or co-receptor usage to make correlations between complex patterns of sequence variability with their corresponding phenotypes [30] . PSSMs is a method for predicting co-receptor usage using a continuous scoring system that takes into account the fact that there exists a continuum of HIV genetic sequences required for shifts in tropism and is interpreted as the propensity to use CXCR4 [24] .
Several studies have examined concordance between phenotypic and genotypic methods for determining coreceptor usage. One study showed relatively poor sensitivity of genotypic approaches as compared with phenotype -the SVM-geno2pheno method performed the best, but had a sensitivity of only 50%; SVM-genomiac performed the worst, with a sensitivity of 22% [36 ] . By contrast, a subsequent study found sensitivities of 88 and 77% for the SVM-geno2pheno and PSSM methods, respectively [37 ] . The varying levels of concordance between genotype and phenotype observed in these studies could be explained by differences in the phenotypic assay used as the comparator, the characteristics of the cohort, the proportion of nonsubtype B infections in the cohort, and the efficiency of population sequencing.
In general, these algorithms perform less well at predicting co-receptor usage of nonsubtype B viruses, which is not surprising considering that most of the algorithms were developed from datasets based mostly on subtype B virus [38 ] . Performance improves when using algorithms developed specifically for the subtype in question [25] , but the number of non-B viruses with genotypic and phenotypic tropism data remains relatively limited.
Preliminary results of a recent study suggest that despite the poor sensitivity of genotypic assays, they perform reasonably well at predicting virologic response to treatment with CCR5 antagonists. The V3 loop sequence was determined in triplicate on screening samples from 1230 patients who enrolled in either MOTIVATE-1 [18 ] , a phase 3 study of maraviroc in treatment-experienced patients with R5 HIV-1 infection, or a sister trial of treatment-experienced patients with CXCR4-using virus [39 ] . The sequence data were interpreted with the aid of either geno2pheno or PSSM [40] . Compared with the original Trofile assay, the two genotypic approaches had sensitivities of 63 and 56%, respectively, and specificities of 91 and 90%, respectively. However, the median log-reduction in plasma HIV-1 RNA at week 8 for patients who received maraviroc was similar for patients characterized as having R5 virus by Trofile or genotype; likewise, similar (although smaller) reductions in plasma HIV-1 RNA were observed for maraviroc-treated patients judged by either assay to have X4 or D/M viruses. One caveat in interpreting results of this study is that the number of patients with discordant results was relatively small, so the power to detect differences in outcome based on screening method was low.
Heteroduplex tracking assays
Another genotype-based approach for determining coreceptor tropism is the DNA heteroduplex tracking assay (HTA). In this method, PCR-amplified V3 sequences from patient samples are hybridized to known V3 sequences of known R5 or X4 viruses and subjected to electrophoresis. Differences in the V3 sequences between the probe and target sequences result in altered electrophoretic mobility due to varying degrees of mismatch in the hybridized DNA molecules. The assay can also estimate the proportion of CCR5-using and CXCR4-using viruses in a population, but sensitivity is highly dependent on the probes used to separate the viral species. One study that tested 50 viral isolates previously characterized by various phenotypic assays showed concordance of 98% between the HTA and phenotypic assays, with a reported sensitivity and specificity for identifying CXCR4-using viruses of 94 and 100%, respectively [41] . Patients with X4 viruses identified by HTA had blunted CD4 cell increases in response to ART.
A commercialized version of the HTA, previously available as the SensiTrop assay from Pathway Diagnostics, was found to have low sensitivity (42%) but high specificity (92.5%) for detecting CXCR4-using viruses in a study of 100-patient samples previously tested by the Trofile assay [42] . An improved version of this assay, SensiTrop II, combined HTA and V3 loop sequence analysis. A comparison of the SensiTrop II and original Trofile assays in samples from 252 treatment-naïve patients found concordance in 79% of results. A low overall proportion of D/M viruses in the sample and the absence of virologic outcome data limit the interpretation of these results. It is notable, however, that a higher proportion of inconclusive results is obtained with the Trofile assay (13%) as compared with the SensiTrop II assay (4%). The SensiTrop II assay has now been replaced by the CE-HDA assay (Quest Diagnostics), which combines V3 loop sequence analysis with heteroduplex analysis performed by capillary electrophoresis, rather than agarose gel electrophoresis [43] .
Clinical use of tropism testing
The principal clinical role of tropism testing is to exclude the presence of detectable D/M or X4 viruses in patients being considered for treatment with a CCR5 antagonist. At this time, phenotypic testing with the enhanced Trofile assay remains the gold standard, but genotypic assays may play a role as well, particularly as more evidence emerges from large clinical studies validating genotypic methods against clinical outcome. Given the high specificity of the genotypic tests, in some settings, it may be reasonable to perform a genotype first. If the result suggests presence of a CXCR4-using virus, no further testing is needed; if the result suggests R5 virus, a confirmatory phenotypic test may be necessary.
Tropism testing may also have a role as a prognostic test. Previous studies had clearly established an association between presence of syncytium-inducing virus and disease progression [4] . A number of studies using contemporary tropism assays show a similar association between presence of D/M or X4 virus and disease progression [41, 44 ,45 ,46 ] . Periodic monitoring of co-receptor usage in patients not receiving ART could be useful for making therapeutic decisions, but additional studies are needed to validate viral tropism as a biomarker for initiating and switching antiretroviral therapy.
Conclusion
Since the identification of CCR5 and CXCR4 co-receptors, much progress has been made in the development of tropism assays and understanding the complex relationship between viral tropism and HIV disease. With the advent of chemokine receptor antagonists, there is additional impetus to decipher the complex determinants of co-receptor usage, and the mechanisms driving evolution of a CXCR4-using virus. Tropism assays are an important tool in these investigations, and in the clinical management of HIV-1 infection. Shepherd JC, Jacobson LP, Qiao W, et al. Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study. J Infect Dis 2008; 198:1104-1112. This study examined longitudinal change in co-receptor usage in a cohort of male seroconverters. CXCR4-using virus was often detected when CD4 cell count was well above the range for the onset of AIDS. The authors propose the use of tropism testing for prognostic purposes in managing HIV infection.
